The Discovery of Benzylidene‐Indenone as Selective Butyrylcholinesterase Inhibitor with Choline Acetyltransferase Gene and Neurite Promoting Abilities

Abstract

AbstractAlzheimer's disease (AD) is a multifactorial and progressive neurodegenerative disease, associated with aging. A total of forty benzylidene‐indenone derivatives were synthesized in search of multi‐target‐directed ligands (MTDL) against AD. Compound 9 was found as the most promising MTDL in this study. It was demonstrated to selectively inhibit human butyrylcholinesterase, increase the gene expression of choline acetyltransferase (CHAT), and promote neurite outgrowth in SH‐SY5Y cells. The compound was also predicted to be able to permeate across the lipid‐infused bilayer, indicating its ability to cross the blood‐brain barrier. The abovementioned findings show compound 9 and its analogs warrant further exploration as potential MTDL anti‐AD agents.